File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection

TitleTenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection
Authors
KeywordsHBeAg
HBsAg
HBV DNA
Hepatitis B
Tenofovir
Issue Date2013
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation
Hepatology International, 2013, v. 7 n. 2, p. 327-334 How to Cite?
AbstractIntroduction: Resistance in nucleoside/nucleotide analog (NA) therapy has always been a challenge in the management of chronic hepatitis B (CHB). Clinical studies: Initially developed for the treatment of HIV infection, early in vitro and clinical observational studies had shown tenofovir disoproxil fumarate (TDF) to be also active against CHB. Recent data from various multicenter phase 3 and 4 clinical trials have confirmed TDF being able to achieve a high viral suppression in both NA-naive and -experienced CHB patients. There are also emerging data on the efficacy of TDF in decompensated CHB. Although there are in vitro studies identifying certain mutation loci associated with a reduced susceptibility to TDF, there have so far been no reports of virologic resistance to TDF in clinical studies. TDF has a favorable safety profile, although more long-term data would be needed. Conclusions: TDF has the makings of an 'ideal' first-line drug for the treatment of CHB. © 2011 Asian Pacific Association for the Study of the Liver.
Persistent Identifierhttp://hdl.handle.net/10722/137379
ISSN
2015 Impact Factor: 1.125
2015 SCImago Journal Rankings: 0.669
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorFung, Jen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2011-08-26T14:24:08Z-
dc.date.available2011-08-26T14:24:08Z-
dc.date.issued2013en_HK
dc.identifier.citationHepatology International, 2013, v. 7 n. 2, p. 327-334en_HK
dc.identifier.issn1936-0533en_HK
dc.identifier.urihttp://hdl.handle.net/10722/137379-
dc.description.abstractIntroduction: Resistance in nucleoside/nucleotide analog (NA) therapy has always been a challenge in the management of chronic hepatitis B (CHB). Clinical studies: Initially developed for the treatment of HIV infection, early in vitro and clinical observational studies had shown tenofovir disoproxil fumarate (TDF) to be also active against CHB. Recent data from various multicenter phase 3 and 4 clinical trials have confirmed TDF being able to achieve a high viral suppression in both NA-naive and -experienced CHB patients. There are also emerging data on the efficacy of TDF in decompensated CHB. Although there are in vitro studies identifying certain mutation loci associated with a reduced susceptibility to TDF, there have so far been no reports of virologic resistance to TDF in clinical studies. TDF has a favorable safety profile, although more long-term data would be needed. Conclusions: TDF has the makings of an 'ideal' first-line drug for the treatment of CHB. © 2011 Asian Pacific Association for the Study of the Liver.en_HK
dc.languageengen_US
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0en_HK
dc.relation.ispartofHepatology Internationalen_HK
dc.rightsThe original publication is available at www.springerlink.com-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectHBeAgen_HK
dc.subjectHBsAgen_HK
dc.subjectHBV DNAen_HK
dc.subjectHepatitis Ben_HK
dc.subjectTenofoviren_HK
dc.titleTenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfectionen_HK
dc.typeArticleen_HK
dc.identifier.emailSeto, WK: wkseto@gmail.comen_HK
dc.identifier.emailYuen, MF: mfyuen@hku.hken_HK
dc.identifier.emailFung, J: jfung@hkucc.hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.authoritySeto, WK=rp01659en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityFung, J=rp00518en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturepostprint-
dc.identifier.doi10.1007/s12072-011-9282-yen_HK
dc.identifier.pmid21688182-
dc.identifier.scopuseid_2-s2.0-84879836796en_HK
dc.identifier.hkuros208944en_US
dc.identifier.hkuros189835-
dc.identifier.hkuros220775-
dc.identifier.volume7-
dc.identifier.issue2-
dc.identifier.spage327en_HK
dc.identifier.epage334en_HK
dc.identifier.isiWOS:000321127600006-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridFung, J=23091109300en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridSeto, WK=23390675900en_HK
dc.identifier.citeulike9476931-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats